Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA.

The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent adducts with DNA, after activation by formaldehyde, has been studied by electrospray ionisation mass spectrometry and HPLC. Mass spectrometry results showed that WEHI-150 could form covalent adducts with d(ACGCGCGT)2 that contained one, two or three covalent links to the octanucleotide, whereas the control drugs (daunorubicin and the anthracenediones mitoxantrone and pixantrone) only formed adducts with one covalent link to the octanucleotide. HPLC was used to examine the extent of covalent bond formation of WEHI-150 with d(CGCGCG)2 and d(CG(5Me)CGCG)2. Incubation of WEHI-150 with d(CG(5Me)CGCG)2 in the presence of formaldehyde resulted in the formation of significantly greater amounts of covalent adducts than was observed with d(CGCGCG)2. In order to understand the observed increase of covalent adducts with d(CG(5Me)CGCG)2, an NMR study of the reversible interaction of WEHI-150 at both CpG and (5Me)CpG sites was undertaken. Intermolecular NOEs were observed in the NOESY spectra of d(ACGGCCGT)2 with added WEHI-150 that indicated that the drug selectively intercalated at the CpG sites and from the major groove. In particular, NOEs were observed from the WEHI-150 H2,3 protons to the H1' protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and C6. By contrast, intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the H2'' proton of the (5Me)C3 in d(CG(5Me)CGCG)2, and between the drug aliphatic protons and the H1' proton of G4. This demonstrated that WEHI-150 preferentially intercalates at (5Me)CpG sites, compared to CpG sequences, and predominantly via the minor groove at the (5Me)CpG site. The results of this study demonstrate that WEHI-150 is likely to form interstrand DNA cross-links, upon activation by formaldehyde, and consequently exhibit greater cytotoxicity than other current anthracenedione drugs.

[1]  S. Cutts,et al.  Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures. , 2015, Organic & biomolecular chemistry.

[2]  G. Capranico,et al.  Novel Ametantrone–Amsacrine Related Hybrids as Topoisomerase IIβ Poisons and Cytotoxic Agents , 2014, Archiv der Pharmazie.

[3]  S. Alcaro,et al.  Aryl ethynyl anthraquinones: a useful platform for targeting telomeric G-quadruplex structures. , 2014, Organic & biomolecular chemistry.

[4]  S. Dogra,et al.  NMR-based structure of anticancer drug mitoxantrone stacked with terminal base pair of DNA hexamer sequence d-(ATCGAT)2 , 2014, Journal of biomolecular structure & dynamics.

[5]  F. Doria,et al.  Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity , 2014 .

[6]  D. Arya,et al.  Dual recognition of the human telomeric G-quadruplex by a neomycin-anthraquinone conjugate. , 2013, Chemical communications.

[7]  G. Hortobagyi,et al.  Anthracyclines in the Treatment of Cancer , 2012, Drugs.

[8]  J. Collins,et al.  DNA binding by pixantrone. , 2010, Organic & biomolecular chemistry.

[9]  J. Collins,et al.  New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. , 2010, Journal of medicinal chemistry.

[10]  G. Varani,et al.  Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA. , 2009, Journal of medicinal chemistry.

[11]  G. Pezzoni,et al.  Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets , 2008, Molecular Pharmacology.

[12]  S. Cutts,et al.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent , 2007, Nucleic acids research.

[13]  A. Nudelman,et al.  Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate , 2007, Molecular Cancer Therapeutics.

[14]  F. Sala,et al.  Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone , 2006, Investigational New Drugs.

[15]  J. Chaires,et al.  A thermodynamic signature for drug-DNA binding mode. , 2006, Archives of biochemistry and biophysics.

[16]  M. Frank-Kamenetskii,et al.  Base-stacking and base-pairing contributions into thermal stability of the DNA double helix , 2006, Nucleic acids research.

[17]  A. Nudelman,et al.  The Power and Potential of Doxorubicin‐DNA Adducts , 2005, IUBMB life.

[18]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[19]  M. Spitz,et al.  Methyl‐CpG‐binding domain 2 , 2004, Cancer.

[20]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[21]  A. Nudelman,et al.  Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). , 2001, Cancer research.

[22]  S. Cutts,et al.  Cytosine Methylation Enhances Mitoxantrone-DNA Adduct Formation at CpG Dinucleotides* , 2001, The Journal of Biological Chemistry.

[23]  J. Smyth,et al.  A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. , 2000, European journal of cancer.

[24]  S. Cutts,et al.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. , 2000, Nucleic acids research.

[25]  C. Cullinane,et al.  Formation of DNA adducts by formaldehyde-activated mitoxantrone. , 1999, Nucleic acids research.

[26]  G. Capranico,et al.  Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. , 1995, Molecular pharmacology.

[27]  A. Wang,et al.  Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. , 1992, Biochemistry.

[28]  D. Faulds,et al.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. , 1991, Drugs.

[29]  D. Patel,et al.  Sequence-dependent conformation of DNA duplexes. The AATT segment of the d(G-G-A-A-T-T-C-C) duplex in aqueous solution. , 1986, The Journal of biological chemistry.

[30]  C. Hanstock,et al.  High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. , 1985, Journal of biomolecular structure & dynamics.

[31]  H. Mouridsen,et al.  Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. , 1984, European journal of cancer & clinical oncology.

[32]  R. Kaptein,et al.  Sequential resonance assignments in 1H NMR spectra of oligonucleotides by two-dimensional NMR spectroscopy. , 1984, Biochemistry.

[33]  J. Feigon,et al.  Two-dimensional proton nuclear magnetic resonance investigation of the synthetic deoxyribonucleic acid decamer d(ATATCGATAT)2. , 1983, Biochemistry.

[34]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[35]  D. States,et al.  A two-dimensional nuclear overhauser experiment with pure absorption phase in four quadrants☆ , 1982 .